Drug Profile
Research programme: cancer therapeutics - GlaxoSmithKline/Vernalis
Latest Information Update: 09 Apr 2021
Price :
$50
*
At a glance
- Originator Vernalis
- Developer GlaxoSmithKline; Vernalis
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 10 Oct 2018 Vernalis has been acquired by Ligand Pharmaceuticals
- 01 Jun 2012 Discontinued for Cancer in USA (unspecified route)
- 08 Aug 2011 Early reasearch is ongoing in USA